Here's Why Sage Therapeutics Rose as Much as 20.3% Today [The Motley Fool]
Sage Therapeutics, Inc. (SAGE)
Last sage therapeutics, inc. earnings: 2/27 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sagerx.com/investor-relations
Company Research
Source: The Motley Fool
The FDA approved an accelerated path through the clinic for the biopharma's next major drug candidate. Maxx Chatsko ( TMFBlacknGold ) Jun 12, 2018 at 5:26PM What happened Shares of Sage Therapeutics ( NASDAQ:SAGE ) soared more than 20% today after the company announced that the U.S. Food and Drug Administration will allow an expedited development program for one of its most promising drug candidates . SAGE-217, being evaluated as a potential treatment for various forms of depression and insomnia, will be allowed to run a single 450-patient study for major depressive disorder to support an application for marketing approval. An ongoing trial in postpartum depression will also now be considered a pivotal trial, and data generated can support an eventual application for approval. As of 3:29 p.m. EDT, the stock had settled to a 18.8% gain. I
Show less
Read more
Impact Snapshot
Event Time:
SAGE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SAGE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SAGE alerts
High impacting Sage Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SAGE
News
- Sage Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]Yahoo! Finance
- INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sage Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.MarketBeat
- Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress [Yahoo! Finance]Yahoo! Finance
- Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business ProgressBusiness Wire
SAGE
Earnings
- 4/25/24 - Miss
SAGE
Sec Filings
- 4/25/24 - Form 10-Q
- 4/25/24 - Form 8-K
- 4/24/24 - Form ARS
- SAGE's page on the SEC website